Free Trial

Novo Nordisk: Catalent Deal

HEALTHCARE

Novo Nordisk (NOVOB: A1/AA-): Catalent transaction

  • Catalent agreed to be acquired by Novo Holdings on 5th Feb 2024 for $16.5bn economic value.
  • Catalent own 50 global sites, of which 3 large fill-and-finish plants in Italy, US and Belgium will be sold to Novo Nordisk for $11bn.
  • The remaining financing of the deal will be fulfilled by a Private Debt agreement with Ares Management and Blue Owl Capital.
  • From the point of view of the public debt markets it is worth noting the size and credit quality that can now be financing in Private Debt.

Novo Nordisk – the bond issuer – will still have to finance the $11bn deal to buy the factories. This is expected to close at the end of 2024.


To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.